Preclinical development of a bispecific TNFα/IL-23 neutralising domain antibody as a novel oral treatment for inflammatory bowel disease双特异性tnf α/IL-23中和域抗体作为炎症性肠病的新型口服疗法的临床前开发SCIENTIFIC REPORTSIF3.92021-09-3019OAAI
Oral Anti-Tumour Necrosis Factor Domain Antibody V565 Provides High Intestinal Concentrations, and Reduces Markers of Inflammation in Ulcerative Colitis PatientsSCIENTIFIC REPORTSIF3.92019-10-0130OAAI
Preclinical Development of a Novel, Orally-Administered Anti-Tumour Necrosis Factor Domain Antibody for the Treatment of Inflammatory Bowel DiseaseSCIENTIFIC REPORTSIF3.92018-03-2150OAAI
The splice variant LOXIN inhibits LOX-1 receptor function through hetero-oligomerizationJOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGYIF4.72008-03-0168PREAI